If you have been reading about anti-doping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== Toxicity === There are two aspects to the harmful effects of plutonium: radioactivity and heavy metal poisoning. Plutonium compounds are radioactive and accumulate in bone marrow. Contamination by plutonium oxide has resulted from nuclear disasters and radioactive incidents, including military nuclear accidents where nuclear weapons have burned. Studies of the effects of these smaller releases, as well as of the widespread radiation poisoning sickness and death following the atomic bombings of Hiroshima and Nagasaki, have provided considerable information regarding the dangers, symptoms and prognosis of radiation poisoning, which in the case of the Japanese survivors was largely unrelated to direct plutonium exposure. The decay of plutonium, releases three types of ionizing radiation: alpha (α), beta (β), and gamma (γ). Either acute or longer-term exposure carries a danger of serious health outcomes including radiation sickness, genetic damage, cancer, and death. The danger increases with the amount of exposure. α-radiation can travel only a short distance and cannot travel through the outer, dead layer of human skin. β-radiation can penetrate human skin, but cannot go all the way through the body. γ-radiation can go all the way through the body. Even though α radiation cannot penetrate the skin, ingested or inhaled plutonium does irradiate internal organs. α-particles generated by inhaled plutonium have been found to cause lung cancer in a cohort of European nuclear workers.
They also made considerable advances in the field of surgery, often without the use of human dissection or animal vivisection. One of the earliest Ayurvedic treatises was the Sushruta Samhita, attributed to Sushruta in the 6th century BCE. It was also an early materia medica, describing 700 medicinal plants, 64 preparations from mineral sources, and 57 preparations based on animal sources.
=== Auxotrophy-based methods to incorporate unnatural amino acids into proteins and proteomes === A large number of unnatural amino acids, which are similar to their canonical counterparts in shape, size and chemical properties, are introduced into the recombinant proteins by means of auxotrophic expression hosts. For example, methionine (Met) or tryptophan (Trp) auxotrophic Escherichia coli strains can be cultivated in a defined minimal medium. In this experimental setup it is possible to express recombinant proteins whose canonical Trp and Met residues are completely substituted with different medium-supplemented related analogs. This methodology leads to a new form of protein engineering, which is not performed by codon manipulation at the DNA level (e.g. oligonucleotide-directed mutagenesis), but by codon reassignments at the level of protein translation under efficient selective pressure. Therefore, the method is referred as selective pressure incorporation (SPI). No organism studied so far encodes other amino acids than the canonical twenty; two additional canonical amino acids (selenocysteine, pyrrolysine) are inserted into proteins by recoding translation termination signals. This boundary can be crossed by adaptive laboratory evolution of metabolically stable auxotrophic microbial strains. For example, the first clearly successful attempt to evolve Escherichia coli that can survive solely on the unnatural amino acid thieno[3,2-b]pyrrolyl) alanine as the only substitute for tryptophan was made in 2015.
I may, however, remark that when the temperature of the ether is only a little above its boiling point, its condensation is a little more rapid than that of atmospheric air. This fact is related to a phenomenon which is exhibited by a great many bodies when passing from the liquid to the solid-state, but which is no longer sensible at temperatures a few degrees above that at which the transition occurs.
Stress may result from rough handling, washing and immersion in water, or transport (e.g., during shipping), which may in some cases contribute to mortality. Inbreeding depression can result in reduced physical health for farmed insects and producers generally make efforts to maintain a more genetically diverse population. Insects may be fed toxin-contaminated grains or plastics/polymers that may reduce their health, depending on the level of inclusion and specific types of these ingredients used (though this is not expected to be common practice in the industry currently).
Sources: en.wikipedia.org
An FDA category that refers to medications used to treat diseases and conditions that occur rarely. There is little financial incentive for the pharmaceutical industry to develop medications for these diseases or conditions. Orphan drug status, however, gives a manufacturer specific financial incentives to develop and provide such medications. (NLM) Outcome
===== Tourism development ===== Paetongtarn Shinawatra has designated tourism as the primary engine for Thailand's economic growth, taking a hands-on role in policy-making and international promotion. Her administration's strategy focuses on elevating Thailand's global image, enhancing tourist safety, and boosting revenue by attracting high-value visitors and establishing the nation as a year-round destination. A key initiative under her leadership is the "Amazing Thailand Grand Tourism and Sports Year 2025", a year-long campaign of festivals and major sporting events designed to attract visitors. This campaign is part of the broader "Ignite Thailand" vision, which aims to establish the country as a global hub for tourism and other key industries. In early 2025, she personally promoted this vision at international travel forums, such as ITB Berlin, setting an ambitious target of attracting 39 million tourists and generating 3.5 trillion baht in revenue for the year. As of early June 2025, Thailand had welcomed over 15 million international visitors for the year, showing a strong recovery. However, some economic research centers have noted that the ambitious full-year targets may face challenges due to a global economic slowdown and increasing regional competition.
The structure of the EcM network depends on the availability of nutrients. When nutrient availability is low, the investment in the underground network is high relative to above-ground growth. Phosphorus is another typically limiting nutrient in many terrestrial ecosystems. Evidence suggests that phosphorus is transferred largely as orthophosphate. Some mat-forming ectomycorrhizas contain ribonucleases capable of rapidly degrading DNA to obtain phosphorus from nuclei.
=== Pharmacokinetics === Like many nucleoside analogues, FIAU is not active right away, it first needs to be converted inside liver cells to become active. In the liver FIAU is converted to its triphosphate form, which is the form that can be used by polymerases. FIAU is the de-aminated product of fiacitabine (FIAC). Upon the entering of FIAC into the cell, cytosine nucleoside deaminase de-aminates FIAC to FIAU.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.